MILAN, July 27 - Goldman Sachs Alternatives, the private equity arm of Goldman Sachs, has agreed to buy control of Numantec from White Bridge Investment, the companies announced. Numantec, headquartered near Mantua in northern Italy, produces a range of healthcare equipment and drug-delivery products.
The manufacturer employs about 600 people and operates seven production facilities across Europe and the United States. White Bridge assembled the business through a sequence of acquisitions following a 2021 investment in Delta Med, an Italian maker of vascular access devices.
No financial terms were disclosed in the companies' announcement. However, a person familiar with the transaction told a news organisation that the sale values Numantec at roughly c700 million.
Under the new ownership, Numantec is expected to persist with its European expansion and to reinforce its footprint in the United States. The company entered the U.S. market last year when it acquired rival Health Line International.
The transaction is anticipated to be finalised in the fourth quarter. JPMorgan served as financial adviser to White Bridge, while Goldman Sachs International advised Goldman Sachs Alternatives.
Background and business footprint
Numantec operates manufacturing facilities both in Europe and in the United States, producing medical devices and drug-delivery systems. The group employs approximately 600 staff across its operations. White Bridge's strategy for Numantec involved a series of purchases that followed an initial 2021 investment in Delta Med, a company known for vascular access products.
Deal details and timing
The parties did not include monetary specifics in their release. The valuation figure reported by a person with knowledge of the matter is not part of the companies' statements but provides context on the scale of the transaction. The closing is expected during the fourth quarter, subject to customary conditions.
Corporate advisers
JPMorgan acted as financial adviser to White Bridge. Goldman Sachs International provided advisory services to the buyer, Goldman Sachs Alternatives.
Outlook
Management under new ownership is expected to maintain Numantec's current trajectory, continuing expansion across European markets and pushing to strengthen its presence in the United States, where the company only recently established operations through its acquisition of Health Line International.